{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:08:24Z","timestamp":1793113704750,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian Rotary Health Research Fund"},{"DOI":"10.13039\/100004312","name":"Eli-Lilly & Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Pregnant women with persistent schizophrenia and related disorders may require ongoing antipsychotic treatment, including clozapine. However, the potential risks of using clozapine during pregnancy and the postnatal period remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>We conducted a nested case-control study using the National Register of Antipsychotic Medication in Pregnancy (NRAMP) database. Our study assessed pregnancy outcomes among Australian women diagnosed with schizophrenia spectrum disorder and treated with clozapine (n\u2005=\u200514) during the first trimester. These women were compared to 2 subgroups: those treated with quetiapine (n\u2005=\u200553) and those not taking any medication (n\u2005=\u200524) during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>We observed higher rates of miscarriage in the clozapine group compared to the quetiapine and drug-free groups. The clozapine group had a higher early pregnancy body mass index but lower overall pregnancy weight gain than the other groups. The prevalence of gestational diabetes was significantly higher in the clozapine group. The percentage of vaginal delivery was higher in the clozapine group than in the other 2 groups. Neonatal outcomes such as gestational age, and Apgar scores were similar across groups. The birth weight was lower in the clozapine group compared to the other 2 groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that pregnant women taking clozapine and their babies have greater adverse outcomes compared to other groups. Clozapine appears to be associated with a greater risk of miscarriages, maternal gestational diabetes, and lower birth weight. However, the gestational age, Apgar scores, and admission to NICU\/SCN were comparable between all groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbae132","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:24:51Z","timestamp":1719969891000},"source":"Crossref","is-referenced-by-count":7,"title":["Clozapine Safety in Pregnancy: A Clinical Study"],"prefix":"10.1093","volume":"52","author":[{"given":"Jayashri","family":"Kulkarni","sequence":"first","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"De Chellis","sequence":"additional","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gilbert","sequence":"additional","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Gavrilidis","sequence":"additional","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Mu","sequence":"additional","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Karimi","sequence":"additional","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"HER Centre Australia, Department of Psychiatry,\u00a0School of Translational Medicine, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"2026032106210308700_CIT0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.schres.2017.09.043","article-title":"Pregnancy exposure to quetiapine\u2014therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes","volume":"195","author":"Paulzen","year":"2018","journal-title":"Schizophr Res."},{"issue":"4","key":"2026032106210308700_CIT0002","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry."},{"issue":"4","key":"2026032106210308700_CIT0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr Bull."},{"issue":"3","key":"2026032106210308700_CIT0004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/YIC.0000000000000162","article-title":"Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months","volume":"32","author":"Stoecker","year":"2017","journal-title":"Int Clin Psychopharmacol."},{"issue":"6","key":"2026032106210308700_CIT0005","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.2018.17040393","article-title":"Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes","volume":"175","author":"Park","year":"2018","journal-title":"Am J Psychiatry."},{"issue":"may11 5","key":"2026032106210308700_CIT0006","doi-asserted-by":"crossref","first-page":"h2298","DOI":"10.1136\/bmj.h2298","article-title":"Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study","volume":"350","author":"Vigod","year":"2015","journal-title":"BMJ."},{"issue":"4","key":"2026032106210308700_CIT0007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.12372","article-title":"Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review","volume":"116","author":"Ennis","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"4","key":"2026032106210308700_CIT0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40263-018-0517-5","article-title":"The safety of second-generation antipsychotics during pregnancy: a clinically focused review","volume":"32","author":"Damkier","year":"2018","journal-title":"CNS Drugs."},{"issue":"3","key":"2026032106210308700_CIT0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1176\/appi.ajp.2015.15040506","article-title":"Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics","volume":"173","author":"Cohen","year":"2016","journal-title":"Am J Psychiatry."},{"issue":"9","key":"2026032106210308700_CIT0010","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry."},{"issue":"4","key":"2026032106210308700_CIT0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","article-title":"Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study","volume":"33","author":"Habermann","year":"2013","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"2026032106210308700_CIT0012","doi-asserted-by":"crossref","first-page":"e94788","DOI":"10.1371\/journal.pone.0094788","article-title":"A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies","volume":"9","author":"Kulkarni","year":"2014","journal-title":"PLoS One."},{"issue":"4","key":"2026032106210308700_CIT0013","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4088\/JCP.v66n0406","article-title":"Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study","volume":"66","author":"McKenna","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"2026032106210308700_CIT0014","doi-asserted-by":"crossref","first-page":"e003062","DOI":"10.1136\/bmjopen-2013-003062","article-title":"Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study","volume":"3","author":"Sadowski","year":"2013","journal-title":"BMJ Open."},{"issue":"7","key":"2026032106210308700_CIT0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archgenpsychiatry.2011.1870","article-title":"Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects","volume":"69","author":"Bod\u00e9n","year":"2012","journal-title":"Arch Gen Psychiatry."},{"issue":"7","key":"2026032106210308700_CIT0016","doi-asserted-by":"crossref","first-page":"e0132280","DOI":"10.1371\/journal.pone.0132280","article-title":"Risk of fetal death after treatment with antipsychotic medications during pregnancy","volume":"10","author":"S\u00f8rensen","year":"2015","journal-title":"PLoS One."},{"issue":"5","key":"2026032106210308700_CIT0017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1192\/bjp.bp.107.041541","article-title":"Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study","volume":"192","author":"Newham","year":"2008","journal-title":"Br J Psychiatry."},{"issue":"4","key":"2026032106210308700_CIT0018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00213-013-3060-6","article-title":"Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study","volume":"228","author":"Peng","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"issue":"8","key":"2026032106210308700_CIT0019","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1176\/appi.ajp.2007.06111886","article-title":"Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes","volume":"164","author":"Newport","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2026032106210308700_CIT0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fphar.2018.00264","article-title":"Clozapine use during pregnancy and lactation: a case-series report","volume":"9","author":"Imaz","year":"2018","journal-title":"Front Pharmacol."},{"issue":"3","key":"2026032106210308700_CIT0021","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005237-200407000-00003","article-title":"Psychotropic medication in pregnancy","volume":"18","author":"Allison","year":"2004","journal-title":"J Perinat Neonat Nurs."},{"key":"2026032106210308700_CIT0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2023.01.030","article-title":"The use of first and second-generation antipsychotic drugs and the potential to develop gestational diabetes mellitus among perinatal patients with psychosis","volume":"254","author":"Kulkarni","year":"2023","journal-title":"Schizophr Res."},{"key":"2026032106210308700_CIT0023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00048670701732723","article-title":"Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy","volume":"42","author":"Kulkarni","year":"2008","journal-title":"Aust N Z J Psychiatry."},{"issue":"6","key":"2026032106210308700_CIT0024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0091217417696739","article-title":"Atypical antipsychotic use and outcomes in an urban maternal mental health service","volume":"51","author":"Hatters Friedman","year":"2016","journal-title":"Int J Psychiatry Med."},{"issue":"11","key":"2026032106210308700_CIT0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1176\/appi.ps.201600408","article-title":"Antipsychotic medication use among publicly insured pregnant women in the United States","volume":"68","author":"Park","year":"2017","journal-title":"Psychiatr Serv."},{"issue":"1","key":"2026032106210308700_CIT0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2288-14-34","article-title":"The thresholds for statistical and clinical significance\u2014a five-step procedure for evaluation of intervention effects in randomised clinical trials","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Med Res Methodol."},{"issue":"12","key":"2026032106210308700_CIT0027","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.2337\/dc16-1194","article-title":"Maternal and neonatal morbidity for women who would be added to the diagnosis of GDM using IADPSG criteria: a secondary analysis of the hyperglycemia and adverse pregnancy outcome study","volume":"39","author":"Waters","year":"2016","journal-title":"Diabetes Care."},{"issue":"suppl 2","key":"2026032106210308700_CIT0028","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2337\/dc07-s224","article-title":"Gestational diabetes, pregnancy hypertension, and late vascular disease","volume":"30","author":"Carpenter","year":"2007","journal-title":"Diabetes Care."},{"key":"2026032106210308700_CIT0029","author":"Welfare, A.I.o.H.a","year":"2023"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/2\/sbae132\/58604311\/sbae132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/2\/sbae132\/58604311\/sbae132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:21:10Z","timestamp":1774088470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbae132\/7717663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,20]]},"published-print":{"date-parts":[[2026,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae132","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2024,7,20]]},"article-number":"sbae132"}}